Page 29 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation
P. 29
CHAPTER 2
FDG-PET as a biomarker for early response in diffuse large B-cell lymphoma as well as in Hodgkin lymphoma? Ready for implementation in clinical practice?
Josée M. Zijlstra Coreline N. Burggraaff Marie José Kersten Sally F. Barrington
On behalf of the EHA Scientific Working Group on Lymphoma
Haematologica. 2016; 101: 1279-1283.
